Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CG-53135; CG53135-05; FGF 20; Fibroblast growth factor-20; rhFGF-20

Latest Information Update: 17 Mar 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CuraGen Corporation
  • Class Anti-inflammatories; Expectorants; Fibroblast growth factors
  • Mechanism of Action Intercellular signalling peptide and protein stimulants; Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stomatitis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammatory bowel diseases; Stomatitis

Most Recent Events

  • 10 Aug 2007 CuraGen completes enrolment in the CLN-12 trial for oral mucositis in the US
  • 01 Jun 2006 CuraGen has initiated enrolment in the CLN-12 trial for oral mucositis in the US, evaluating a single dose of velafermin
  • 24 Feb 2006 Data from a media release have been added to the adverse events and Mouth disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top